• Penumbra, Inc. recently initiated a voluntary Class II recall of its RED 68 Reperfusion Catheter (specific RED68KIT lots) after manufacturing issues were found that may cause the device to fracture, affecting customers across the US and multiple international markets.
• This recall arrives just after Penumbra reported second-quarter 2026 results showing higher sales of US$390.05 million but lower net income of US$34.81 million compared with the prior year, adding fresh questions about product quality control and future regulatory scrutiny.
• We will now examine how this voluntary catheter recall, and the manufacturing risks it highlights, could influence Penumbra’s existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

Penumbra Investment Narrative Recap

To own Penumbra, you generally need to believe in the long term demand for minimally invasive stroke and vascular interventions and in the company’s ability to execute safely at scale. In the near term, many eyes are on how upcoming clinical data and product launches translate into procedure growth, while the biggest risk now looks more operational: whether the RED 68 Class II recall points to broader manufacturing quality issues. If the issue is contained to specific lots, the impact may remain limited.

The recall lands just after Penumbra’s second quarter 2026 results, where sales rose to US$390.05 million but net income declined to US$34.81 million compared with a year earlier. That mix of higher revenue and lower earnings makes this product quality event more relevant, as it could influence future cost structure, regulatory interactions, and how investors think about the trade off between growth investments and tighter operational controls around upcoming catalysts.

But against that growth story, the emerging risk around manufacturing quality and potential regulatory scrutiny is something investors should be very aware of before they...

Penumbra's narrative projects $2.1 billion revenue and $311.7 million earnings by 2029.

Uncover how Penumbra's forecasts yield a $363.36 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming about US$2.0 billion in revenue and US$275 million in earnings by 2029, yet this recall could challenge that path just as much as the reliance on rapid VTE and PE procedure growth that you saw in the more cautious narrative.

Explore 2 other fair value estimates on Penumbra - why the stock might be worth as much as 12% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Penumbra research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Penumbra research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Penumbra's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.